Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. ImmunityBio, Inc. is among the best biotech stocks.

TheFly reported on January 20 that Piper Sandler raised its price target on IBRX to $7 from $5 and maintained an Overweight rating. According to the update, U.S. ANKTIVA net sales increased by almost 700% year over year to $113 million in 2025. Revenue is expected to reach $180 million in 2026. A possible label expansion for ANKTIVA in 2027 may be supported by positive QUILT-2.005 data anticipated in Q4 2026, according to the firm’s encouraging interim results.

Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)'s ANKTIVA Following QUILT Data

Additionally, on January 23, ImmunityBio, Inc. (NASDAQ:IBRX) reported Phase 2 QUILT-3.078 results in recurrent GBM. According to the studies, the longest survival was 12 months, and the median overall survival has not achieved, meaning that 19 out of 23 patients are still living. The regimen had a reasonable safety profile, immunological competence was preserved, and severe lymphopenia improved (ALC ≥1.4 ×10³/µL).

ImmunityBio, Inc. (NASDAQ:IBRX) is a U.S. biotechnology company developing next‑generation immunotherapies and vaccines that enhance the natural immune system to fight cancers and infectious diseases.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.